These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
197 related articles for article (PubMed ID: 39091896)
1. The growing research toolbox for SLC13A5 citrate transporter disorder: a rare disease with animal models, cell lines, an ongoing Natural History Study and an engaged patient advocacy organization. Brown TL; Bainbridge MN; Zahn G; Nye KL; Porter BE Ther Adv Rare Dis; 2024; 5():26330040241263972. PubMed ID: 39091896 [TBL] [Abstract][Full Text] [Related]
2. Characterizing a rare neurogenetic disease, SLC13A5 citrate transporter disorder, utilizing clinical data in a cloud-based medical record collection system. Spelbrink EM; Brown TL; Brimble E; Blanco KA; Nye KL; Porter BE Front Genet; 2023; 14():1109547. PubMed ID: 37025451 [No Abstract] [Full Text] [Related]
3. Mapping the Metabolic Niche of Citrate Metabolism and Chen F; Willenbockel HF; Cordes T Metabolites; 2023 Feb; 13(3):. PubMed ID: 36984771 [TBL] [Abstract][Full Text] [Related]
4. Disruption of the sodium-dependent citrate transporter SLC13A5 in mice causes alterations in brain citrate levels and neuronal network excitability in the hippocampus. Henke C; Töllner K; van Dijk RM; Miljanovic N; Cordes T; Twele F; Bröer S; Ziesak V; Rohde M; Hauck SM; Vogel C; Welzel L; Schumann T; Willmes DM; Kurzbach A; El-Agroudy NN; Bornstein SR; Schneider SA; Jordan J; Potschka H; Metallo CM; Köhling R; Birkenfeld AL; Löscher W Neurobiol Dis; 2020 Sep; 143():105018. PubMed ID: 32682952 [TBL] [Abstract][Full Text] [Related]
6. Mutations in the Na(+)/citrate cotransporter NaCT (SLC13A5) in pediatric patients with epilepsy and developmental delay. Klotz J; Porter BE; Colas C; Schlessinger A; Pajor AM Mol Med; 2016 May; 22():310-21. PubMed ID: 27261973 [TBL] [Abstract][Full Text] [Related]
7. Consequences of NaCT/SLC13A5/mINDY deficiency: good versus evil, separated only by the blood-brain barrier. Kopel JJ; Bhutia YD; Sivaprakasam S; Ganapathy V Biochem J; 2021 Feb; 478(3):463-486. PubMed ID: 33544126 [TBL] [Abstract][Full Text] [Related]
8. Recessive mutations in SLC13A5 result in a loss of citrate transport and cause neonatal epilepsy, developmental delay and teeth hypoplasia. Hardies K; de Kovel CG; Weckhuysen S; Asselbergh B; Geuens T; Deconinck T; Azmi A; May P; Brilstra E; Becker F; Barisic N; Craiu D; Braun KP; Lal D; Thiele H; Schubert J; Weber Y; van 't Slot R; Nürnberg P; Balling R; Timmerman V; Lerche H; Maudsley S; Helbig I; Suls A; Koeleman BP; De Jonghe P; Brain; 2015 Nov; 138(Pt 11):3238-50. PubMed ID: 26384929 [TBL] [Abstract][Full Text] [Related]
10. Metformin, valproic acid, and starvation induce seizures in a patient with partial SLC13A5 deficiency: a case of pharmaco-synergistic heterozygosity. Kopel J; Grooms A; Ganapathy V; Clothier J Psychiatr Genet; 2021 Feb; 31(1):32-35. PubMed ID: 33290383 [TBL] [Abstract][Full Text] [Related]
11. Discovery and characterization of novel inhibitors of the sodium-coupled citrate transporter (NaCT or SLC13A5). Huard K; Brown J; Jones JC; Cabral S; Futatsugi K; Gorgoglione M; Lanba A; Vera NB; Zhu Y; Yan Q; Zhou Y; Vernochet C; Riccardi K; Wolford A; Pirman D; Niosi M; Aspnes G; Herr M; Genung NE; Magee TV; Uccello DP; Loria P; Di L; Gosset JR; Hepworth D; Rolph T; Pfefferkorn JA; Erion DM Sci Rep; 2015 Dec; 5():17391. PubMed ID: 26620127 [TBL] [Abstract][Full Text] [Related]
12. Novel Approaches to Studying SLC13A5 Disease. Beltran AS Metabolites; 2024 Jan; 14(2):. PubMed ID: 38392976 [TBL] [Abstract][Full Text] [Related]
13. SLC13A5 Deficiency Disorder: From Genetics to Gene Therapy. Goodspeed K; Liu JS; Nye KL; Prasad S; Sadhu C; Tavakkoli F; Bilder DA; Minassian BA; Bailey RM Genes (Basel); 2022 Sep; 13(9):. PubMed ID: 36140822 [TBL] [Abstract][Full Text] [Related]
14. Growth and Overall Health of Patients with Brown TL; Nye KL; Porter BE Metabolites; 2021 Oct; 11(11):. PubMed ID: 34822404 [TBL] [Abstract][Full Text] [Related]
15. Functional analysis of a species-specific inhibitor selective for human Na+-coupled citrate transporter (NaCT/SLC13A5/mINDY). Higuchi K; Kopel JJ; Sivaprakasam S; Jaramillo-Martinez V; Sutton RB; Urbatsch IL; Ganapathy V Biochem J; 2020 Nov; 477(21):4149-4165. PubMed ID: 33079129 [TBL] [Abstract][Full Text] [Related]
16. Epilepsy and EEG Phenotype of SLC13A5 Citrate Transporter Disorder. Yang QZ; Spelbrink EM; Nye KL; Hsu ER; Porter BE Child Neurol Open; 2020; 7():2329048X20931361. PubMed ID: 32551328 [TBL] [Abstract][Full Text] [Related]
17. A home run for human NaCT/SLC13A5/INDY: cryo-EM structure and homology model to predict transport mechanisms, inhibitor interactions and mutational defects. Jaramillo-Martinez V; Ganapathy V; Urbatsch IL Biochem J; 2021 Jun; 478(11):2051-2057. PubMed ID: 34101804 [TBL] [Abstract][Full Text] [Related]
18. Structure and inhibition mechanism of the human citrate transporter NaCT. Sauer DB; Song J; Wang B; Hilton JK; Karpowich NK; Mindell JA; Rice WJ; Wang DN Nature; 2021 Mar; 591(7848):157-161. PubMed ID: 33597751 [TBL] [Abstract][Full Text] [Related]